Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

239
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
239
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

277
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
277
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
204
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

243
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
243

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026
Same author

Rising overweight and obesity in Swiss psoriatic arthritis patients, 2007-2022: a nationwide registry-population comparison.

Clinical and experimental rheumatology·2026
Same author

A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".

Dermatology and therapy·2026
Same author

The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study.

Dermatology and therapy·2026
Same author

Association Between Bimekizumab's Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II.

Dermatology and therapy·2026

Related Experiment Video

Updated: Sep 17, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.2K

Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV

Ulrich Mrowietz1, Rachel Sommer2, Sascha Gerdes1

  • 1Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Psoriasis (Auckland, N.Z.)
|July 3, 2025
PubMed
Summary

Tildrakizumab significantly improved well-being, quality of life, and reduced symptoms in moderate-to-severe psoriasis patients over 52 weeks. The interleukin-23p19 inhibitor demonstrated good safety and tolerability in a real-world setting.

Keywords:
RWEWHO-5 Well-being Indexeffectivenesspsoriasisreal-world evidencetildrakizumabwell-being

More Related Videos

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
06:13

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain

Published on: March 1, 2024

1.1K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K

Related Experiment Videos

Last Updated: Sep 17, 2025

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.2K
Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
06:13

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain

Published on: March 1, 2024

1.1K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K

Area of Science:

  • Dermatology
  • Immunology
  • Clinical Research

Background:

  • Psoriasis significantly impacts patients' social, emotional, and physical well-being.
  • Tildrakizumab is an approved interleukin-23p19 inhibitor for moderate-to-severe plaque psoriasis.

Purpose of the Study:

  • To assess the effect of tildrakizumab on the overall well-being of patients with psoriasis.
  • Evaluate effectiveness, quality of life (QoL), symptomatology, treatment satisfaction, and impact on partners.

Main Methods:

  • 24-month observational study (POSITIVE) of adults with moderate-to-severe psoriasis treated with tildrakizumab.
  • Utilized WHO-5, PASI, DLQI-R, TSQM-9, and FamilyPso outcome measures.
  • Reported 52-week interim data from 400 patients.

Main Results:

  • Significant improvements observed in WHO-5 well-being scores (p < 0.0001).
  • Mean PASI scores decreased significantly (p < 0.0001), with high achievement of PASI ≤ 3/≤ 1.
  • Significant reductions in DLQI-R scores (p < 0.0001) and FamilyPso impact (p < 0.0001).
  • High treatment satisfaction reported across effectiveness, convenience, and global domains.
  • Low incidence of adverse events (24.0%) and treatment discontinuation due to AEs.

Conclusions:

  • Tildrakizumab effectively enhances patient well-being, QoL, and clinical outcomes in moderate-to-severe psoriasis.
  • Demonstrates a favorable safety and tolerability profile in real-world clinical practice.
  • Contributes to value-based long-term healthcare for psoriasis management.